NASDAQ:EYEN Eyenovia (EYEN) Stock Price, News & Analysis $1.77 -0.26 (-12.81%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.03 (-1.69%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eyenovia Stock (NASDAQ:EYEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eyenovia alerts:Sign Up Key Stats Today's Range$1.70▼$2.0250-Day Range$0.92▼$2.0352-Week Range$0.85▼$124.80Volume1.24 million shsAverage Volume412,019 shsMarket Capitalization$5.01 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company OverviewEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Read More… Eyenovia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreEYEN MarketRank™: Eyenovia scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingEyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageEyenovia has only been the subject of 1 research reports in the past 90 days.Read more about Eyenovia's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eyenovia's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.97% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 3.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.97% of the float of Eyenovia has been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eyenovia has recently decreased by 3.73%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.84 News SentimentEyenovia has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Eyenovia this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 25.84% of the stock of Eyenovia is held by institutions.Read more about Eyenovia's insider trading history. Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address EYEN Stock News HeadlinesEyenovia Advances Merger Talks With Betaliq And Targets FDA Filing For Optejet DeviceMay 22 at 4:30 AM | nasdaq.comEyenovia provides update on potential merger and Optejet developmentMay 20 at 7:43 AM | msn.comMissed the Last 10,000% Surge? Here’s Your Next ChanceWe’ve uncovered small-cap stocks that have delivered big wins—before the rest of the market caught on. We don’t rely on luck—we rely on data, trends, and research. Our team is constantly scanning the market to spot hidden opportunities before they explode. What if you could get alerts on high-potential companies—before the crowd?May 23, 2025 | Fierce Analyst (Ad)Eyenovia Reports Q1 2025 Progress and FinancialsMay 20 at 12:33 AM | tipranks.comEyenovia, Inc. Provides Merger Update with Betaliq and Financial Results for Q1 2025May 19, 2025 | quiverquant.comEyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial ResultsMay 19, 2025 | globenewswire.comEyenovia (EYEN) Expected to Announce Quarterly Earnings on WednesdayMay 19, 2025 | americanbankingnews.comEyenovia Faces Nasdaq Delisting Over Equity ShortfallMay 4, 2025 | investing.comSee More Headlines EYEN Stock Analysis - Frequently Asked Questions How have EYEN shares performed this year? Eyenovia's stock was trading at $11.68 at the start of the year. Since then, EYEN stock has decreased by 84.8% and is now trading at $1.77. View the best growth stocks for 2025 here. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) announced its earnings results on Monday, May, 19th. The company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($7.20) by $5.61. The firm earned $1.60 million during the quarter, compared to analysts' expectations of $1.60 million. Eyenovia had a negative net margin of 114,639.41% and a negative trailing twelve-month return on equity of 1,108.24%. When did Eyenovia's stock split? Eyenovia's stock reverse split before market open on Monday, February 3rd 2025. The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Eyenovia IPO? Eyenovia (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. Who are Eyenovia's major shareholders? Top institutional shareholders of Eyenovia include Lasry Marc (1.08%), Virtu Financial LLC (0.82%) and Simplex Trading LLC. Insiders that own company stock include Stuart M Grant, Tsontcho Ianchulev, Michael M Rowe, Charles E Iv Mather, Ellen R Strahlman and Bren Kern. View institutional ownership trends. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Plug Power (PLUG), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Pfizer (PFE), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/19/2025Today5/23/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EYEN CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+12.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($58.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,260,000.00 Net Margins-114,639.41% Pretax Margin-114,639.41% Return on Equity-1,108.24% Return on Assets-139.36% Debt Debt-to-Equity Ratio0.58 Current Ratio0.74 Quick Ratio0.55 Sales & Book Value Annual Sales$57,336.00 Price / Sales87.86 Cash FlowN/A Price / Cash FlowN/A Book Value$16.32 per share Price / Book0.11Miscellaneous Outstanding Shares2,830,000Free Float1,294,000Market Cap$5.04 million OptionableOptionable Beta0.76 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:EYEN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.